John Libbey Eurotext

Epileptic Disorders

The Educational Journal of the International League Against Epilepsy

Quinidine therapy and therapeutic drug monitoring in four patients with KCNT1 mutations Volume 21, numéro 1, February 2019

Illustrations

  • Figure 1
  • Figure 2
Auteurs
1 National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
2 Seirei Hamamatsu General Hospital, Department of Child Neurology, Hamamatsu
3 Yokohama City University Graduate School of Medicine, Department of Human Genetics, Yokohama
4 Hamamatsu University School of Medicine, Department of Biochemistry, Hamamatsu,
5 Shizuoka Children's Hospital, Department of Cardiology, Shizuoka
6 Department of Pediatrics School of Medicine, Fukuoka University, Fukuoka, Japan
* Correspondence: Shinsaku Yoshitomi National Epilepsy Center, NHO Shizuoka Institute of Epilepsy and Neurological Disorder, 886 Urushiyama, Aoi-ku, Shizuoka 420-8688, Japan
  • Mots-clés : KCNT1, EIMFS, quinidine, serum concentration, arrhythmia, migrating focal seizures
  • DOI : 10.1684/epd.2019.1026
  • Page(s) : 48-54
  • Année de parution : 2019

Aims

Several recent studies have reported potassium sodium-activated channel subfamily T member 1 (KCNT1) mutations in epilepsy patients on quinidine therapy. The efficacy and safety of quinidine for epilepsy treatment, however, remains controversial.